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In The Lancet Infectious Diseases Robert Heyderman 
and colleagues1 report on a phase 2 clinical trial 
comparing the safety and immunogenicity of a 
trivalent glycoconjugate vaccine directed against 
group B streptococci (GBS) in pregnant HIV-infected 
and uninfected women in Malawi and South Africa. In 
my opinion the most important message of this Article 
is that ﬁ nally—more than 40 years after the magnitude 
of neonatal GBS disease was ﬁ rst recognised—a 
promising vaccine against GBS is studied in the target 
group of pregnant women; and in particular, it is 
tested in women with HIV in sub-Saharan Africa where 
the disease burden is supposed to be highest. 
During the early 1970s, the attention to GBS 
changed greatly when three hallmark manuscripts 
reported simultaneously that GBS had emerged as the 
leading pathogen in neonatal sepsis in the USA.2 At 
present, GBS is one of the most important pathogens 
worldwide, leading to neonatal sepsis, death, and 
disability.3 In sub-Saharan Africa—and particularly 
in pregnant women with HIV—the risk for invasive 
neonatal GBS disease is supposed to be many times 
higher than in the USA and Europe.
In the 1990s, a ﬁ rst milestone towards successful 
containment was reached when consensus recom-
mendations for the prevention of neonatal 
GBS disease were issued by the key professional 
organisations in the USA, the American College of 
Obstetricians and the American Academy of Pediatrics, 
together with the Centers for Disease Control and 
Prevention. In brief, the recommendations were 
to screen pregnant women for GBS colonisation 
(screening-based approach), and to give intrapartum 
antibiotic prophylaxis to women positive for GBS or to 
women with speciﬁ c risk factors (risk-based approach). 
Consequently, from 1993 to 1998, the incidence of 
neonatal early onset GBS disease (which is deﬁ ned as 
occurring between days 0 to 7 postpartum) decreased 
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confusion prevails when patients receive clinical care 
in resource-limited areas with non-speciﬁ c but serious 
febrile illnesses. Sensitive, accurate, inexpensive, and 
point-of-care diagnostic assays are needed that can 
distinguish enteric fever from other common non-
speciﬁ c febrile illnesses that need individualised treat-
ment, including invasive non-typhoidal salmonellosis, 
rickettsiosis, leptospirosis, malaria, and arboviral and 
other viral infections.9 Unfortunately, many decades 
might pass until the most impoverished members of our 
global community live in the conditions that mitigate 
their risk of acquiring such diseases. In the meantime, 
crucial methods that enhance our ability to care for 
these patients are either absent or have been lost. Now 
is the time to initiate coordinated control programmes 
against typhoid before the storm hits—we have been 
warned.
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by 65%.4 In fact, intrapartum antibiotic prophylaxis 
proved successful but was bought dearly—doubling 
the rate of antibiotic use during labour. Moreover, the 
incidence of neonatal late-onset GBS sepsis (occurring 
from day 8 to 90) remained fairly unaﬀ ected. 
In the 1980s, clinician scientists Carol Baker and 
Dennis Kasper began investigating polysaccharide-
based GBS vaccines.5 As early as 1988, they were able 
to show that maternal immunisation against GBS 
is feasible.6 However, the immunogenicity of GBS 
polysaccharide-based vaccines was weak. By contrast, 
conjugate vaccines prepared with GBS type-speciﬁ c 
capsular poly saccharides coupled to protein antigens 
proved to induce stronger immune responses than 
GBS vaccines based only on polysaccharides, and were 
ﬁ rst tested in a phase 1 trial in 1996.7 Since then, not 
much progress has been made.
For almost half a century, invasive disease due to 
GBS has been recognised as a threat to the health of 
newborn infants and their mothers in both rich and 
resource-poor countries. But the development of GBS 
vaccines has been hampered for decades by many 
obstacles, not least by the scarcity of sponsorship by 
industrial partners. Heyderman and colleagues’ study, 
together with concurrent phase 2 trials, constitutes 
an important step forward towards prevention of 
neonatal GBS sepsis.1,8,9 However, questions remain. 
Why is the vaccine less immunogenic in women 
with HIV? Is immunogenicity aﬀ ected by baseline 
antibody concentrations as it seems to be, and if so, 
could antibody concentrations in turn be aﬀ ected 
by GBS carriage rates, at least of speciﬁ c serotypes? 
Finally, researchers still need to determine the dosage 
of the vaccine and whether a booster dose should be 
used. Nevertheless, the results of this trial1 show that 
prevention of neonatal GBS infection by vaccination is 
feasible in women with and without HIV. 
Maternal immunisation has the potential to protect 
the pregnant woman, fetus, and newborn infant 
from vaccine preventable diseases. Maternal IgG is 
actively transported across the placenta, providing 
passive immunity. At present, inactivated inﬂ uenza, 
tetanus toxoid, and acellular pertussis vaccines are 
recommended during pregnancy.10 The time has come 
to further develop GBS vaccines, to address issues not 
covered in the present study, and to initiate larger 
studies designed to prove not only immunogenicity 
but also protection from disease and mortality.8,11
Heyderman and colleagues’ study is also relevant 
beyond neonatal sepsis; GBS has emerged as an 
important bacterial pathogen in general. In the USA, 
GBS is now ranked second (18%) after pneumococci 
(58%) among causative agents leading to bacterial 
meningitis across all age groups, having surpassed 
meningococci (13·9%) and Haemophilus inﬂ uenzae 
type b (6·7%).12 Therefore, a forthcoming GBS vaccine 
would hopefully, not only save thousands of lives 
of newborn babies, but also lives of children, adults, 
and elderly people. The trial by Heyderman and 
colleagues adds substantially towards the realisation 
of this vision.
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